Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Mechanistic aspects of the final step of heme b biosynthesis in Gram-positive bacteria

Award Number: R15GM114787
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2015
PERIOD OF PERFORMANCE END DATE: 08/31/2023

Group Awards By:

View Award Description

Mechanistic aspects of the final step of heme b biosynthesis in Gram-positive bacteria - Project Summary Coproheme decarboxylase (ChdC, also known as HemQ) catalyzes the final step in a recently delineated pathway for heme b biosynthesis in critically important Gram-positive pathogens like Staphylococcus aureus, Mycobacterium tuberculosis, and Bacillus anthracis. ChdC binds and activates two molecules of H2O2 at its substrate coproheme iron center, leading to the sequential oxidative decarboxylation of the propionate side chains at porphyrin ring positions 2 and 4 (P2 and P4) to form heme b. Previous studies have inferred a ChdC mechanism in which the oxidation is mediated by a nearby tyrosine. This tyrosine is first oxidized by an ill- defined high-valent heme species in what is thought to be a proton-coupled electron transfer reaction to yield the corresponding tyrosyl radical (Y•). Evidence suggests that H-atom transfer from the ring-adjacent methylene carbon of P2 or P4 to Y• sets up the last oxidation step by the heme FeIV=O to release CO2 and form the 2- or 4- vinyl group. The aims of the project are threefold: 1) Understand the mechanism by which coproheme III is transferred from ferrochelatase (CpfC) to ChdC; 2) Elucidate the nature and mechanistic roles of the prompt and heretofore unidentified reactive coproheme- and harderoheme-centered intermediates in the ChdC-catalyzed reaction of coproheme III with H2O2; and 3) Examine the mechanistic steps unique to the oxidative decarboxylation of the harderoheme III P4 group. The first aim will identify and assess the protein- protein interactions required to transfer the coproheme from CpfC to ChdC without suffering the toxic effects of releasing it into the cell. This aim will be addressed using reactivity assays, kinetic studies, variants of ChdC and CpfC, and biophysical methods, including analytical ultracentrifugation and native gradient gel electrophoresis. The second two aims will be addressed with spectroscopic (resonance Raman, electron paramagnetic resonance, and transient absorbance), kinetic (stopped flow and freeze-quench), and cyroradiolytic sample preparation methods to gain insight into the structural and electronic properties of the ChdC prompt intermediates that direct their reactivities toward product. S. aureus is a leading cause of skin and soft tissue infections, bacteremia, osteomyelitis, and endocarditis. Paramount to our national health is the timely development of effective clinical strategies against the growing threat of drug-resistant bacterial infections. Thus, ChdC and CpfC from S. aureus will be developed as a paradigm for understanding the final step in heme b biosynthesis and the role of protein protein complexation in protecting the cell from off-pathway reactivity and toxicity of hemes in Gram-positive pathogens. Since the ChdC proteins are only found in Gram- positive bacteria and not in humans and as heme is essential during infection, ChdC holds promise as a yet unexploited target for antimicrobial therapeutics, once the mechanistic aspects of its function are understood.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$240 )
2024	2019	NORTH DAKOTA STATE UNIVERSITY	1301 12TH AVE N	FARGO	ND	58102	CASS	USA	Biomedical Research and Research Training	000	2	1/5/2024	COMPETING CONTINUATION	-$240
														Subtotal = -$240

Issue Date FY: 2019 ( Subtotal = $435,000 )
2019	2019	NORTH DAKOTA STATE UNIVERSITY	1919 UNIVERSITY DR N, STE 102	FARGO	ND	58102	CASS	USA	Biomedical Research and Research Training	002	2	9/19/2019	COMPETING CONTINUATION	$240
2019	2019	NORTH DAKOTA STATE UNIVERSITY	1919 UNIVERSITY DR N, STE 102	FARGO	ND	58102	CASS	USA	Biomedical Research and Research Training	000	2	9/12/2019	COMPETING CONTINUATION	$435,000
2019	2015	NORTH DAKOTA STATE UNIVERSITY	1919 UNIVERSITY DR N, STE 102	FARGO	ND	58102	CASS	USA	Biomedical Research and Research Training	001	1	9/19/2019	NEW	-$240
														Subtotal = $435,000

Issue Date FY: 2015 ( Subtotal = $334,950 )
2015	2015	NORTH DAKOTA STATE UNIVERSITY	P.O. BOX 5405	FARGO	ND	58105	CASS	USA	Biomedical Research and Research Training	000	1	6/29/2015	NEW	$334,950
														Subtotal = $334,950

Grand Total All Awards = $769,710

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Mechanistic aspects of the final step of heme b biosynthesis in Gram-positive bacteria

Award Number: R15GM114787

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2015

PERIOD OF PERFORMANCE END DATE: 08/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer